Skip to main content Skip to main navigation menu Skip to site footer

Antibiogram of Acinetobacter baumannii isolated from Intensive Care Unit at Prof. dr. I.G.N.G. Ngoerah Hospital in 2020-2022

  • Indramawan Setyojatmiko ,
  • Ni Nengah Dwi Fatmawati ,
  • Ni Made Adi Tarini ,

Abstract

Background: Acinetobacter baumannii infection is a severe problem since it tends to be multi-resistant to many antibiotics. This study aimed to determine the prevalence of A. baumannii isolated from blood, urine, and sputum cultures and their antibiotic resistance patterns.

Methods: Data of A. baumanii isolated from clinical specimens of Intensive Care Unit (ICU) wards patients were collected retrospectively from laboratory records in the Clinical Microbiology Department of Prof. Dr. I. G. N. G. Ngoerah General Hospital during 2020-2022. Identification and antimicrobial susceptibility tests were conducted using the Vitek-2 Compact system (bioMérieux, France). Isolates resistant to ≥ 3 antibiotic classes were categorized as multidrug-resistant (MDR) A. baumanii.

Results: A. baumanii collected from sputum, blood, and urine in Intensive Care Unit (ICU) wards were 63%, 13%, and 7.5% from 2020 until 2022. Most A. baumanii isolates in 2020, 2021, and 2022 were susceptible to Amikacin, which was 75%, 78%, and 76%, respectively. Furthermore, the isolates that were susceptible to Trimethoprim/Sulfamethoxazole were 66%, 81%, and 72%, followed by Tigecycline, 80%, 61%, and 56% respectively. A. baumanii, however, showed low sensitivity to Meropenem even though susceptibility is getting higher each year. Almost all the isolates were resistant to ceftriaxone.

Conclusions: Acinetobacter baumannii isolates isolated during 2020-2022 showed high resistance to penicillin, cephalosporin and fluoroquinolones. Although A. baumanii was resistant to carbapenem, its susceptibility tends to increase throughout the 3 years of this study. These data could be considered for empirical therapy of A. baumanii infections.

References

  1. Saharman YR, Karuniawati A, Severin JA, Verbrugh HA. Infections and antimicrobial resistance in intensive care units in lower-middle-income countries: a scoping review. Antimicrob Resist Infect Control. 2021;10(1):1–19.
  2. Raut S, Rijal KR, Khatiwada S, Karna S, Khanal R, Adhikari J, et al. Trend and characteristics of acinetobacter baumannii infections in patients attending Universal College of Medical Sciences, Bhairahawa, Western Nepal: A longitudinal study of 2018. Infect Drug Resist. 2020;13:1631–41.
  3. Fahy S, O’Connor JA, Lucey B, Sleator RD. Hospital Reservoirs of Multidrug Resistant Acinetobacter Species—The Elephant in the Room! Br J Biomed Sci. 2023;80(March):1–7.
  4. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy. 2009;65(2):233–8.
  5. Kohlenberg A, Brümmer S, Higgins PG, Sohr D, Piening BC, De Grahl C, et al. Outbreak of carbapenem-resistant Acinetobacter baumannii carrying the carbapenemase OXA-23 in a German university medical centre. J Med Microbiol. 2009;58(11):1499–1507.
  6. Alotaibi T, Abuhaimed A, Alshahrani M, Albdelhady A, Almubarak Y, Almasari O. Prevalence of multidrug-resistant Acinetobacter baumannii in a critical care setting: A tertiary teaching hospital experience. SAGE Open Med. 2021;9(1):20503121211001144.
  7. Uwingabiye J, Lemnouer A, Baidoo S, Frikh M, Kasouati J, Maleb A, et al. Intensive care unit-acquired Acinetobacter baumannii infections in a Moroccan teaching hospital: Epidemiology, risk factors and outcome. Germs. 2017;7(4):193–205.
  8. Cucunawangsih, Wiwing V, Lugito NPH. Antimicrobial Susceptibility of in a Teaching Hospital : A Two-Year Observation. Open J Med Microbiol. 2015;5(June):85–89.
  9. Chang D, Sharma L, Dela Cruz CS, Zhang D. Clinical Epidemiology, Risk Factors, and Control Strategies of Klebsiella pneumoniae Infection. Front Microbiol. 2021;12(December):1–9.
  10. Choi J, Ki M, Kwon HJ, Park B, Bae S, Oh CM, et al. Health indicators related to disease, death, and reproduction [Internet]. Journal of Preventive Medicine and Public Health. 2019;52(1):14–20.
  11. Darwinata AE, Tarini NMA HL. Detection of carbapenemase by Modified Hodge test, distribution, resistence pattern of MDR A. baumannii in Sanglah General Hospital. In: 8th Nat Congress Indonesian Society Clin Microbiol. 2012.
  12. Organisation Mondiale de la Santé. WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. Saudi Med J. 2017;38(1):444–445.
  13. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327.
  14. Ayobami O, Willrich N, Harder T, Okeke IN, Eckmanns T, Markwart R. The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis. Emerg Microbes Infect. 2019;8(1):1747–1759.
  15. Kim UJ, Kim HK, An JH, Cho SK, Park KH, Jang HC. Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections. Chonnam Med J. 2014;50(2):37.
  16. European Centre for Disease Prevention and Control. Rapid Risk Assessment: Carbapenem-resistance Acinetobacter baumannii in healthcare settings. Rapid Risk Assessment. 2016;2015. [Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/8-Dec-2016-RRA-Acinetobacter baumannii-Europe.pdf] [Accessed on: 4th September 2023].
  17. Truong WR, Hidayat L, Bolaris MA, Nguyen L, Yamaki J. The antibiogram: Key considerations for its development and utilization. JAC Antimicrob Resist. 2021;3(2):1–6.
  18. CLSI. CLSI M100-ED29: 2021 Performance Standards for Antimicrobial Susceptibility Testing, 30th Edition. Vol. 40, CLSI. 2020;1(1):50–51.
  19. Clinical and laboratory standards institute. Clinical and Laboratory Standards Institute. CLSI Document. Performance standards for antimicrobial. M100-S22. 2022.
  20. CLSI. M100 Performance Standards for Antimicrobiafile. 2021. [Available at: https://clsi.org/standards/products/microbiology/documents/m100/] [Accessed on: 1st September 2023].
  21. Sileem AE, Said AM, Meleha MS. Acinetobacter baumannii in ICU patients: A prospective study highlighting their incidence, antibiotic sensitivity pattern and impact on ICU stay and mortality. Egyptian Journal of Chest Diseases and Tuberculosis. 2017;66(4):693–698.
  22. Ballouz T, Aridi J, Afif C, Irani J, Lakis C, Nasreddine R, et al. Risk factors, clinical presentation, and outcome of Acinetobacter baumannii bacteremia. Front Cell Infect Microbiol. 2017;7:1–8.
  23. Gustawan IW, Satari HI, Amir I, Astrawinata DA. Gambaran Infeksi Acinetobacter baumannii dan Pola Sensitifitasnya terhadap Antibiotik. Sari Pediatri. 2016;16(1):35-40.
  24. Dharma BDA, Mulyantari NK, Prabawa IPY. Analisis korelasi kadar serum prokalsitonin dengan jumlah leukosit pada penderita dengan kecurigaan sepsis di RSUP Sanglah, Bali, Indonesia. Intisari Sains Medis. 2020;11(1):179-182.
  25. Syaiful I, Mertaniasih NM, Alimsardjono L, Endraswari PD, Utariani A, Utomo B. Critical priority Multidrug-Resistant Organisms (MDROs) secondary infection among COVID-19 patients: hidden threat during a pandemic? A retrospective study. Bali Medical Journal. 2023;12(1):416–422.
  26. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to Tigecycline. Pharmacotherapy. 2007;27(8):1198–1201.
  27. Syaiful I, Widodo ADW, Endraswari PD, Alimsardjono L, Utomo B, Arfijanto MV. The association between biofilm formation ability and antibiotic resistance phenotype in clinical isolates of gram-negative bacteria: a cross-sectional study. Bali Medical Journal. 2023;12(1):1014–1020.
  28. Baran A, Atelik M, Arslan Y, Demirk H. Evaluation of risk factors in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii. Bali Medical Journal. 2020;9(1):253–258.
  29. Bialvaei AZ, Kouhsari E, Salehi-Abargouei A, Amirmozafari N, Ramazanzadeh R, Ghadimi-Daresajini A, et al. Epidemiology of multidrug-resistant Acinetobacter baumannii strains in Iran: a systematic review and meta-analysis. Journal of Chemotherapy. 2017;29(6):327–337.
  30. Primaningtyas W, Pamungkasari EP. Factors Causing Acinetobacter Baumannii Resistance to Carbapenem Antibiotics in Patients with Healthcare Associated Infection (HCAI) at Dr. Moewardi Hospital, Surakarta. Indonesian Journal of Medicine. 2017;02(02):125–138.

How to Cite

Setyojatmiko, I., Fatmawati, N. N. D., & Tarini, N. M. A. (2023). Antibiogram of Acinetobacter baumannii isolated from Intensive Care Unit at Prof. dr. I.G.N.G. Ngoerah Hospital in 2020-2022. Intisari Sains Medis, 14(3), 1023–1027. https://doi.org/10.15562/ism.v14i3.1831

HTML
0

Total
0

Share

Search Panel

Indramawan Setyojatmiko
Google Scholar
Pubmed
ISM Journal


Ni Nengah Dwi Fatmawati
Google Scholar
Pubmed
ISM Journal


Ni Made Adi Tarini
Google Scholar
Pubmed
ISM Journal